Real-world management, resource use, patient-reported outcomes and adherence in patients receiving direct oral anticoagulants for first stroke attributed to non-valvular atrial fibrillation in secondary care: A UK mixed-methods observational study
Authors:
Open Access
- 23 May 2025
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (5) , e0321621
Abstract
This real-world study investigated the patient-related factors, characteristics, and outcomes of adult patients with non-valvular atrial fibrillation (NVAF) receiving a direct oral anticoagulant (DOAC) for secondary stroke prevention. This was a multi-centre, mixed-methods, non-interventional study conducted in 8 UK secondary care National Health Service centres. The study included adult patients who presented with first ischaemic stroke associated with NVAF without previous anticoagulants. Group 1 included all patients. Group 2 is comprised of prospectively enrolled patients who were initiated on apixaban (n = 49), edoxaban (n = 39) or rivaroxaban (n = 5) post-first stroke from Group 1. The primary objective (Group 1) was to describe patients’ demographics, clinical characteristics, and medical history, stratified by the anticoagulant prescribed. The secondary objectives (Group 2) were to describe the patient management pathways, hospital resource use and clinical assessments associated with DOAC treatment, and the patient-reported satisfaction and experience of DOAC treatment. 234 patients were recruited from 8 centres (Group 1). Baseline CHA2DS2-VASc risk scores ranged from 2–7; 70% (157/224) had a score of ≥4. 86% (n = 202/234) of patients presented with stroke at accident and emergency. For Group 2, the median time from stroke to first DOAC dose was 6 (IQR, 2.0–10.2; n = 88) days; 50% patients had ≥ 1 outpatient visit recorded related to AF or DOACs. At 3 and 6 months, 73% (46/63) and 83% (43/52) had high (score of 8) Morisky Medication Adherence Scale score (MMAS-8), respectively. No patients reported being dissatisfied at 3 or 6 months post-DOAC initiation. The study findings demonstrate high levels of adherence, persistence, and treatment satisfaction in the 6 months post-initiation of DOAC after first stroke attributable to NVAF in patients. The presented results provide clinicians with valuable insights into the experience of post-stroke patients with NVAF receiving treatment with a DOAC for secondary prevention of stroke during the 6 months post-stroke.Keywords
Funding Information
- Daiichi-Sankyo UK Ltd
This publication has 40 references indexed in Scilit:
- Early versus Later Anticoagulation for Stroke with Atrial FibrillationNew England Journal of Medicine, 2023
- Direct Oral Anticoagulant (DOAC) Dosing in Patients with Non-valvular Atrial Fibrillation (NVAF) in the United Kingdom: A Retrospective Cohort Study Using CPRD Gold DatabaseAdvances in Therapy, 2022
- Antithrombotic therapy in patients with liver disease: population-based insights on variations in prescribing trends, adherence, persistence and impact on stroke and bleedingThe Lancet Regional Health - Europe, 2021
- Satisfaction With Oral Anticoagulants Among Patients With Atrial Fibrillation: A Prospective Observational StudyCJC Open, 2021
- Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe studyEuropean Heart Journal - Cardiovascular Pharmacotherapy, 2020
- International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registriesAmerican Heart Journal, 2017
- Improving the measurement of self-reported medication nonadherence: Response to AuthorsJournal of Clinical Epidemiology, 2011
- Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillationJACC, 2004
- Prevalence of Diagnosed Atrial Fibrillation in AdultsJAMA, 2001
- Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates 11Reprints are not available.The American Journal of Cardiology, 1998